Procept Biorobotics (PRCT) Azione Prezzo
Procept Biorobotics Prezzo
Il fatturato è cresciuto a un tasso composto del 95,5% annuo negli ultimi 6 anni, raggiungendo 304,47 Mio. USD. Il margine netto di Procept Biorobotics si attesta al -31,4%, in aumento rispetto al -208,8% di alcuni anni fa. Gli analisti fissano un target di prezzo mediano di 20,50 USD, ovvero il 1,3% sopra il prezzo attuale. Su 21 analisti, 10 valutano il titolo come acquisto — nel complesso un consenso Mantenere.
Procept Biorobotics Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
Procept Biorobotics Azione e analisi azionaria
Domande frequenti sull'azione Procept Biorobotics
The business model of PROCEPT BioRobotics Corp. is focused on developing and commercializing innovative surgical technologies. The company specializes in the design and manufacturing of the AquaBeam® System, a robotic surgical platform used for treating patients with prostate conditions. This state-of-the-art technology combines the precision of a robotic arm with the benefits of water-jet technology to provide minimally invasive procedures with increased accuracy and efficiency. PROCEPT BioRobotics Corp. aims to improve patient outcomes by delivering advanced solutions in the field of urology through their AquaBeam® System, positioning themselves as leaders in robotic-assisted surgeries for prostate treatment.
PROCEPT BioRobotics Corp is primarily active in the medical device and healthcare industries.
The main competitors of PROCEPT BioRobotics Corp in the market include companies such as Intuitive Surgical, Inc., Medtronic Plc, and Johnson & Johnson.
PROCEPT BioRobotics Corp is a renowned medical device company specializing in surgical robotics. Founded in 2002, the company has made significant strides in improving the treatment of Benign Prostatic Hyperplasia (BPH). PROCEPT BioRobotics Corp developed the revolutionary Aquablation® therapy, which utilizes advanced robotic technology to precisely and efficiently remove prostate tissue without causing significant side effects. This minimally invasive procedure has garnered recognition for its effectiveness in improving the quality of life for patients suffering from BPH. With a strong focus on innovation and patient care, PROCEPT BioRobotics Corp continues to lead the way in robotic surgical solutions for urologic conditions.
PROCEPT BioRobotics Corp has achieved several significant milestones. The company developed and gained regulatory approval for its groundbreaking Aquablation therapy, a minimally invasive treatment for benign prostatic hyperplasia (BPH). They successfully launched their flagship product, the AquaBeam® Robotic System, in the US and other international markets. PROCEPT BioRobotics Corp expanded its global presence by establishing strategic partnerships and growing its distribution network. They have consistently demonstrated strong clinical outcomes, with numerous peer-reviewed publications supporting the effectiveness and safety of Aquablation therapy. The company's milestones highlight its commitment to revolutionizing BPH treatment and improving patient outcomes worldwide.
PROCEPT BioRobotics Corp is primarily present in the United States.
PROCEPT BioRobotics Corp is committed to its core values of innovation, collaboration, and patient-centricity. With a corporate philosophy focused on developing transformative solutions for patients and healthcare providers, the company aims to revolutionize the field of surgical robotics. PROCEPT BioRobotics Corp strives to enhance patient outcomes by offering its advanced Aquablation® technology, enabling precise and personalized therapy for patients with urologic conditions. By incorporating cutting-edge robotics, the company prioritizes effective treatments and improved patient experiences. Through continuous research, development, and partnerships, PROCEPT BioRobotics Corp dedicates itself to pushing boundaries and revolutionizing the healthcare industry.
Gli analisti fissano attualmente un prezzo obiettivo medio di 22,13 USD per l’azione Procept Biorobotics (mediana: 20,50 USD), pari a +9,6 % rispetto all’ultimo prezzo. Il consenso si basa su 21 giudizi di analisti.
21 analisti valutano attualmente l’azione Procept Biorobotics: 10 raccomandano l’acquisto, 10 la tenuta e 1 la vendita. Per il 2026 gli analisti si aspettano per Procept Biorobotics ricavi pari a 395,29 Mio. USD e un utile per azione di -1,66 USD.
Convertita al tasso di cambio attuale, l’azione Procept Biorobotics quota 18,12 EUR (20,23 USD).
L’azione Procept Biorobotics (PRCT) è quotata su 1 borse, tra cui: NASDAQ (PRCT).
PROCEPT BioRobotics Corp is a global provider of innovative robotic solutions for urological surgeries. The company aims to improve patient's quality of life while increasing the efficiency of surgeons. PROCEPT BioRobotics Corp's main product is the Aquablation® System, which uses robotic technology to treat benign prostatic hyperplasia. The Aquablation® System offers numerous advantages such as faster recovery, reduced risk of complications, and immediate symptom relief. The company also offers training and education services to healthcare professionals. PROCEPT BioRobotics Corp follows a "Razor-and-Blades" business model, offering the Aquablation® System at an affordable price while generating revenue from the regular supply of consumables. The company prioritizes regulatory compliance and has implemented a global quality management system. In summary, PROCEPT BioRobotics Corp is a leading company in the field of robotic urology, providing an excellent alternative to traditional surgical treatments.
Il attesa fatturato di Procept Biorobotics ammonta a 395,29 Mio. USD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di Procept Biorobotics ammonta a -92,89 Mio. USD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di Procept Biorobotics è attualmente -12,21. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Procept Biorobotics.
Il rapporto prezzo/fatturato (P/S) di Procept Biorobotics è attualmente 2,87. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Procept Biorobotics.
Il Quality Score AlleAktien per Procept Biorobotics è 4/10.
L'ISIN di Procept Biorobotics è US74276L1052. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il ticker di Procept Biorobotics è PRCT. Con questo simbolo di borsa vengono negoziate le azioni Procept Biorobotics in borsa.
Azione Procept Biorobotics
Gruppo di pari di Procept Biorobotics
Procept Biorobotics Ticker
Procept Biorobotics FIGI
Altre metriche e analisi di Procept Biorobotics in Deep Dive.
La nostra analisi azionaria dell'azione Procept Biorobotics include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Procept Biorobotics. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: